Cliff Asness's ABT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 1.08 M shares of Abbott Laboratories (ABT) worth $135.14 M, representing 0.07% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 53 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in ABT, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2013, adding 2.22 M shares. Largest reduction occurred in Q2 2016, reducing 2.49 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -80,986 | Reduce 6.98% | 1.08 M | $125.29 |
| Q3 2025 | -704,290 | Reduce 37.79% | 1.16 M | $133.12 |
| Q2 2025 | +147,176 | Add 8.57% | 1.86 M | $135.14 |
| Q1 2025 | +222,565 | Add 14.90% | 1.72 M | $132.30 |
| Q4 2024 | +166,342 | Add 12.53% | 1.49 M | $113.11 |
| Q3 2024 | +456,590 | Add 52.41% | 1.33 M | $112.82 |
| Q2 2024 | +38,676 | Add 4.65% | 871,196 | $103.79 |
| Q1 2024 | +29,160 | Add 3.63% | 832,520 | $113.38 |
| Q4 2023 | -278,909 | Reduce 25.77% | 803,360 | $110.07 |
| Q3 2023 | -113,358 | Reduce 9.48% | 1.08 M | $96.85 |
| Q2 2023 | -453,281 | Reduce 27.49% | 1.2 M | $108.25 |
| Q1 2023 | -162,069 | Reduce 8.95% | 1.65 M | $100.34 |
| Q4 2022 | +139,394 | Add 8.34% | 1.81 M | $109.43 |
| Q3 2022 | -182,643 | Reduce 9.85% | 1.67 M | $96.76 |
| Q2 2022 | -28,635 | Reduce 1.52% | 1.85 M | $107.99 |
| Q1 2022 | -25,868 | Reduce 1.36% | 1.88 M | $118.36 |
| Q4 2021 | -82,775 | Reduce 4.16% | 1.91 M | $140.74 |
| Q3 2021 | -104,884 | Reduce 5.00% | 1.99 M | $118.13 |
| Q2 2021 | -213,605 | Reduce 9.25% | 2.1 M | $115.73 |
| Q1 2021 | +638,726 | Add 38.22% | 2.31 M | $119.84 |
| Q4 2020 | +366,431 | Add 28.08% | 1.67 M | $108.25 |
| Q3 2020 | +277,685 | Add 27.03% | 1.3 M | $106.05 |
| Q2 2020 | +430,235 | Add 72.08% | 1.03 M | $88.81 |
| Q1 2020 | -289,276 | Reduce 32.64% | 596,916 | $78.91 |
| Q4 2019 | -541,184 | Reduce 37.91% | 886,192 | $86.86 |
| Q3 2019 | -750,271 | Reduce 34.45% | 1.43 M | $83.67 |
| Q2 2019 | +139,598 | Add 6.85% | 2.18 M | $83.76 |
| Q1 2019 | +46,449 | Add 2.33% | 2.04 M | $79.31 |
| Q4 2018 | +757,437 | Add 61.37% | 1.99 M | $72.33 |
| Q3 2018 | +286,021 | Add 30.17% | 1.23 M | $73.36 |
| Q2 2018 | +422,853 | Add 80.50% | 948,142 | $60.99 |
| Q1 2018 | +114,895 | Add 28.00% | 525,289 | $59.92 |
| Q4 2017 | +317,078 | Add 339.79% | 410,394 | $57.07 |
| Q3 2017 | -31,757 | Reduce 25.39% | 93,316 | $53.36 |
| Q2 2017 | -509,318 | Reduce 80.28% | 125,073 | $48.61 |
| Q1 2017 | +460,477 | Add 264.77% | 634,391 | $44.41 |
| Q4 2016 | -867,261 | Reduce 83.30% | 173,914 | $38.41 |
| Q3 2016 | -527,821 | Reduce 33.64% | 1.04 M | $42.29 |
| Q2 2016 | -2.49 M | Reduce 61.39% | 1.57 M | $39.31 |
| Q1 2016 | -670,146 | Reduce 14.16% | 4.06 M | $41.83 |
| Q4 2015 | +933,762 | Add 24.57% | 4.73 M | $44.91 |
| Q3 2015 | +2.11 M | Add 125.06% | 3.8 M | $40.22 |
| Q2 2015 | +337,306 | Add 24.96% | 1.69 M | $49.08 |
| Q1 2015 | -216,242 | Reduce 13.80% | 1.35 M | $46.33 |
| Q4 2014 | -126,057 | Reduce 7.44% | 1.57 M | $45.02 |
| Q3 2014 | -333,896 | Reduce 16.47% | 1.69 M | $41.59 |
| Q2 2014 | -805,281 | Reduce 28.43% | 2.03 M | $40.90 |
| Q1 2014 | -1.78 M | Reduce 38.64% | 2.83 M | $38.51 |
| Q4 2013 | +388,175 | Add 9.18% | 4.62 M | $38.33 |
| Q3 2013 | -145,668 | Reduce 3.33% | 4.23 M | $33.19 |
| Q2 2013 | +4.37 M | Add 0.00% | 4.37 M | $34.88 |
| Q4 2012 | +2.15 M | Add 0.00% | 2.15 M | $65.50 |
Cliff Asness's Abbott Laboratories Investment FAQs
Cliff Asness first purchased Abbott Laboratories (ABT) in Q4 2012, acquiring 2,154,659 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Abbott Laboratories (ABT) for 53 quarters since Q4 2012.
Cliff Asness's largest addition to Abbott Laboratories (ABT) was in Q2 2013, adding 4,374,153 shares worth $152.57 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 1,078,593 shares of Abbott Laboratories (ABT), valued at approximately $135.14 M.
As of the Q4 2025 filing, Abbott Laboratories (ABT) represents approximately 0.07% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Abbott Laboratories (ABT) was 4,733,740 shares, as reported at the end of Q4 2015.